priors.science/reviews/heart-failure-management

Heart Failure Management

The current evidence on 22 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

22claims tracked
279primary papers reviewed
2 Jun 2026latest evidence review
Weeklyre-scored against new papers
7 Established · 11 Likely · 4 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableAngiotensin receptor-neprilysin inhibitor reduces mortality versus ACE inhibitor or angiotensin receptor blocker in heart failure with reduced ejection fractionPharmEstablished89%17
StableSGLT2 inhibitors reduce mortality in heart failure with reduced ejection fractionPharmEstablished88%17
StableMineralocorticoid receptor antagonist reduces mortality in heart failure with reduced ejection fractionPharmEstablished87%15
StableCardiac resynchronisation therapy reduces mortality in heart failure with reduced ejection fraction and left bundle branch blockCRTEstablished86%14
StableSGLT2 inhibitors reduce heart failure hospitalisation in heart failure with preserved ejection fractionHFPEFEstablished86%16
StablePrimary prevention implantable cardioverter-defibrillator reduces sudden cardiac deathIcdEstablished86%18
StableBeta-blockers reduce mortality in heart failure with reduced ejection fractionPharmEstablished86%12
StableSacubitril/valsartan does not reduce mortality in heart failure with preserved ejection fractionHFPEFLikely84%11
StableAcetazolamide improves decongestion in acute decompensated heart failureAdhfLikely78%19
StableHeartMate 3 superior to axial-flow left ventricular assist devicesLvadLikely78%17
StableFinerenone reduces heart failure events in heart failure with mildly reduced or preserved ejection fractionHFPEFLikely77%18
StableSGLT2 inhibitors improve outcomes in acute decompensated heart failureAdhfLikely75%13
StableVericiguat reduces events in worsening heart failure with reduced ejection fractionNovelLikely75%16
StableImplantable cardioverter-defibrillator benefit diminishes in patients over 70 yearsIcdLikely73%14
StableIntravenous iron reduces heart failure hospitalisationIronLikely73%17
StableLeft ventricular assist device destination therapy improves survival in end-stage heart failureLvadLikely73%12
StableQuadruple therapy superior to three-drug regimensPharmLikely73%17
StableIntravenous iron does not reduce all-cause mortality in heart failureIronLikely68%15
StableCardiac resynchronisation therapy with defibrillator and with pacemaker have similar all-cause mortalityCRTUncertain62%12
StableImplantable cardioverter-defibrillator reduces all-cause mortality in the contemporary eraIcdUncertain59%18
StableLeft bundle branch pacing achieves superior resynchronisation versus conventional biventricular cardiac resynchronisation therapyCRTUncertain57%15
StableVericiguat neutral for primary endpoint in stable heart failure with reduced ejection fractionNovelUncertain54%17
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic